Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation

被引:13
作者
Roman-Garcia, Sara [1 ]
Merino-Cortes, Sara V. [1 ]
Gardeta, Sofia R. [1 ]
de Bruijn, Marjolein J. W. [2 ]
Hendriks, Rudi W. [2 ]
Carrasco, Yolanda R. [1 ]
机构
[1] CSIC, CNB, Dept Immunol & Oncol, Cell Dynam Lab B, Madrid, Spain
[2] Erasmus Univ, Dept Pulm Med, Med Ctr, Rotterdam, Netherlands
关键词
B cells; Btk; immune synapse; actin cytoskeleton; shuttling/scaffold; kinase; cell activation; PROTEIN-DEFICIENCY; ACTIVATION; BTK; ADHESION; ANTIGEN; ACTIN; LYMPHOCYTES; DYNAMICS; TEC; EXPRESSION;
D O I
10.3389/fimmu.2018.02027
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Bruton's tyrosine kinase (Btk) has a key role in the signaling pathways of receptors essential for the B lymphocyte response. Given its implication in B cell-related immunodeficiencies, leukemias/lymphomas and autoimmunity, Btk is studied intensely and is a target for therapy. Here, using primary B cells from distinct mouse models and the pharmacological inhibitors ibrutinib and acalabrutinib, we report distinct roles for Btk in antigen-triggered immune synapse (IS) formation. Btk recruitment to the plasma membrane regulates the B cell ability to trigger IS formation as well as its appropriate molecular assembly; Btk shuttling/scaffold activities seem more relevant than the kinase function on that. Btk-kinase activity controls antigen accumulation at the IS through the PLC gamma 2/Ca2+ axis. Impaired Btk membrane-recruitment or kinase function likewise alters antigen-triggered microtubule-organizing center (MTOC) polarization to the IS, B cell activation and proliferation. Data also show that, for B cell function, IS architecture is as important as the quantity of antigen that accumulates at the synapse.
引用
收藏
页数:16
相关论文
共 50 条
[41]   Genotype-phenotype correlation in Bruton's tyrosine kinase deficiency [J].
Teimourian, Shahram ;
Nasseri, Saeed ;
Pouladi, Nima ;
Yeganeh, Mehdi ;
Aghamohammadi, Asghar .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2008, 30 (09) :679-683
[42]   Merits and Pitfalls in the Characterization of Covalent Inhibitors of Bruton's Tyrosine Kinase [J].
Harris, Christopher M. ;
Foley, Sage E. ;
Goedken, Eric R. ;
Michalak, Mark ;
Murdock, Sara ;
Wilson, Noel S. .
SLAS DISCOVERY, 2018, 23 (10) :1040-1050
[43]   Bruton's Tyrosine Kinase Mediates the Synergistic Signalling between TLR9 and the B Cell Receptor by Regulating Calcium and Calmodulin [J].
Kenny, Elaine F. ;
Quinn, Susan R. ;
Doyle, Sarah L. ;
Vink, Paul M. ;
van Eenennaam, Hans ;
O'Neill, Luke A. J. .
PLOS ONE, 2013, 8 (08)
[44]   Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect [J].
Wang, Haoran ;
Guo, Hao ;
Yang, Jingyi ;
Liu, Yanyan ;
Liu, Xingchen ;
Zhang, Qing ;
Zhou, Keshu .
EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2022, 11 (01)
[45]   Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase [J].
Davids, Matthew S. ;
Brown, Jennifer R. .
FUTURE ONCOLOGY, 2014, 10 (06) :957-967
[46]   Clinical potential of targeting Bruton's tyrosine kinase [J].
Uckun, Fatih M. .
INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2008, 27 (1-2) :43-69
[47]   Bruton's Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis [J].
Garg, Neeta ;
Padron, Elizabeth Jordan ;
Rammohan, Kottil W. ;
Goodman, Courtney Frances .
JOURNAL OF CLINICAL MEDICINE, 2022, 11 (20)
[48]   Bruton's Tyrosine Kinase Inhibitors in B-Cell Non-Hodgkin's Lymphomas [J].
Alinari, L. ;
Quinion, C. ;
Blum, K. A. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 (05) :469-477
[49]   Bruton's Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies [J].
Lou, Yan ;
Owens, Timothy D. ;
Kuglstatter, Andreas ;
Kondru, Rama K. ;
Goldstein, David M. .
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (10) :4539-4550
[50]   HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton's Tyrosine Kinase Inhibitor Ibrutinib [J].
Lu, Ziwen ;
Wang, Zhixin ;
Tu, Zhigang ;
Liu, Hanqing .
FRONTIERS IN PHARMACOLOGY, 2022, 13